AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03346161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care American Society of Plastic Surgeons booklet Breast Reconstruction
Description: -Booklet from the American Society of Plastic Surgeons about how to choose a breast reconstruction surgeon, what to expect during surgery, what is breast reconstruction, risks of breast reconstruction, recovery, costs, and questions to ask surgeon about breast reconstruction
Study NCT03346161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision tool
Description: -Interactive web based tool. Provides detail about breast reconstruction, asks participant questions about health and medications to personalize risks for breast reconstruction outcome. The tool also goes into pros/cons of breast reconstruction, talks about differences between types of reconstruction, helps people weigh when to have reconstruction (immediate vs. delayed), shows participants representative photos of breast reconstruction outcomes, and assesses patients' knowledge and preferences
Study NCT03346161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group - Outcome Measures
Description: * Section 1 Knowledge (primary outcome) - set of multiple choice questions about breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict Scale - 4 questions with yes/no answers dealing with participant's certainty about surgery (it total score less than 4, indicates higher decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appoint answers range from 0=no effort to 9=every effort.
Study NCT03346161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Group - Outcome Measures
Description: * Section 1 Knowledge and Values Clarification Questions - set of multiple choice questions about the participants feelings on breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict SURE measure - 4 questions with yes/no answers dealing with participant's conflicts on surgery (if total score less than 4, indicates higher clinical significant decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction (for those who have a clinical visit)~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appointment answers range from 0=no effort to 9=every effort (for those who have a clinical visit).
Study NCT03346161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographic and Background Questions
Description: * Asks 15 questions~* Age, education, ethnicity, race, combined household income, zip code, disease stage, (3) questions about health insurance, (4) questions about participant's ability to work with numbers, heath literacy, health insurance status, and (1) question on if participant spoke to another provider about breast reconstruction decision
Study NCT03346161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demographic and Background Questions
Description: * Asks 15 questions~* Age, education, ethnicity, race, combined household income, zip code, disease stage, (3) questions about health insurance, (4) questions about participant's ability to work with numbers, heath literacy, health insurance status, and (1) question on if participant spoke to another provider about breast reconstruction decision
Study NCT02502097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 50 mg tablet, administered by mouth
Study NCT02502097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to gefapixant, tablet administered by mouth
Study NCT00203476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Study NCT00203476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colestipol
Study NCT00203476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Study NCT02293148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863 75 mg
Description: A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
Study NCT02293148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863 500 mg
Description: A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
Study NCT02558296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg tablet to match active comparator
Study NCT02266511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomax®, Norman II facility
Study NCT02266511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomax®, Nishine facility
Study NCT03125395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: Participants received LUM/IVA every q12h.
Study NCT03171649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETRAINER-S1
Description: It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise.
Study NCT03171649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy
Study NCT03171649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy
Study NCT03909789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant based bioequivalent Nitrate supplementation
Description: The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
Study NCT03909789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02700906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
Study NCT02700906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
Study NCT03109496 — intervention group
Intervention type: OTHER
Intervention: Collection of body fluids/swabs
Description: Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.
Study NCT01875653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)
Description: Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
Study NCT01875653 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous PBMCs in GM-CSF (MC)
Description: Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
Study NCT00755053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole, vaginal ovule
Description: Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
Study NCT00755053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole, vaginal tablet
Description: Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
Study NCT02527811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
Study NCT00403520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental 1
Description: Drug: Donepezil Hydrochloride 10 mg orally for 12 months
Study NCT00403520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Drug: Placebo Matching placebo orally for 12 months
Study NCT01099722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutiform
Description: inhaler 2 puffs bd daily
Study NCT01099722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbohaler
Description: 2 puffs bd daily
Study NCT00571493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will receive bortezomib in four dose cohorts ( .8. 1.0, 1.3, 1.5 mg/m²). Patients will receive bortezomib on days -11, -8, -5, and -2 before infusion of autologous stem cells.
Study NCT00571493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)
Description: All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells.
Study NCT03835195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Disease Management Program
Description: The attention is carried out in a single physical place, in the city of Medellin. The scheme of intervention in the comprehensive Diabetes Clinic is based on the concept of disease management. The intervention is composed of 5 phases, which apply to all the patients cared for in the institution (access, reception, entry, clinical consultation, management plan, education, pharmaceutical care). The healthcare team consists of 5 endocrinologists, an endocrinologist pediatrician, 7 general practitioners trained in diabetes, 5 pharmacists trained in diabetes and certified in education for patients with diabetes and 3 nutritionists.
Study NCT03835195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Process
Description: The patients are treated in the cardiovascular risk clinic (general practitioners) of their Primary Healthcare Provider Institution or by specialists in internal medicine, pediatrics or endocrinology in the different Provider Institutions of Health Services of the insurance service network of health or in private doctors' offices assigned to the insurer. In some cases there is assisted consultation (general practitioner - specialist). There is no defined periodicity for follow-up; Appointments are assigned to need, according to the criteria of the treating physicians. In some cases there is remission to educational activities, not necessarily focused on type 1 diabetes.
Study NCT03159429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
Study NCT03159429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nasal breathing rehabilitation
Description: The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
Study NCT01874899 — intervention group
Intervention type: DEVICE
Intervention: RestoreSensor Neurostimulation
Study NCT02124837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Park walk during lunch break
Study NCT02124837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation during lunch break
Study NCT01672580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to vitamin use
Description: Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village
Study NCT01672580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure to vitamin use
Description: Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village
Study NCT01672580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to water chlorination
Description: Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village
Study NCT01672580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure to water chlorination
Description: Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village
Study NCT01672580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high in-degree
Description: Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree
Study NCT01672580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nominated by random
Description: Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual
Study NCT04467684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 100 mg
Description: Single oral dose
Study NCT04467684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 200 mg
Description: Single oral dose
Study NCT04467684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 400 mg
Description: Single oral dose
Study NCT04467684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 800 mg
Description: Single oral dose
Study NCT04467684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-0406 1,000 mg
Description: Single oral dose
Study NCT04467684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Color and size matched placebo
Study NCT01941810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin supplement
Description: Given PO
Study NCT01941810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01941810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01941810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04111380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and nab-paclitaxel
Description: Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
Study NCT00456222 — intervention group
Intervention type: BEHAVIORAL
Intervention: Disrupting or changing the timing or the duration of sleep
Description: Disrupting or changing the timing or the duration of sleep
Study NCT01187355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)
Description: Investigational multi-purpose disinfecting solution used by subjects as specified in use instructions provided for the care of study contact lenses, 30 days.
Study NCT01187355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: renu fresh Multi-Purpose Solution (MPS)
Description: Commercially available multi-purpose solution used by subjects as indicated for care of study contact lenses, 30 days.
Study NCT01187355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses
Description: Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
Study NCT01187355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
Study NCT00389610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreas vaccine
Description: Given intradermally
Study NCT01499940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
Study NCT02199184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02199184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02199184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02199184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT02199184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02199184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02199184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02691507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram Skin Barrier Emulsion
Description: EpiCeram Skin Barrier Emulsion
Study NCT02691507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Product 1% Colloidal Oatmeal Balm
Description: Experimental Product 1% Colloidal Oatmeal Balm
Study NCT03354195 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.
Description: All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)
Study NCT01948596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Study NCT03743168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent stretching protocol
Description: Intermittent stretching protocol of five sets of 1 minute and15 second rest
Study NCT03743168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous stretch
Description: 2 minutes continuous stretch
Study NCT03788512 — intervention group
Intervention type: OTHER
Intervention: observational only- no intervention
Description: observational only- no intervention